​

Edgewise Therapeutics (EWTX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

EWTX Stock Forecast

Edgewise Therapeutics (EWTX) stock forecast, based on 11 Wall Street analysts, predicts a 12-month average price target of $53.10, with a high of $66.00 and a low of $36.00. This represents a 35.08% increase from the last price of $39.31.

$15 $26 $37 $48 $59 $70 High: $66 Avg: $53.1 Low: $36 Last Closed Price: $39.31

EWTX Stock Rating

Edgewise Therapeutics stock's rating consensus is Buy, based on 11 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 9 Buy (81.82%), 2 Hold (18.18%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 11 0 2 9 Strong Sell Sell Hold Buy Strong Buy

EWTX Price Target Upside V Benchmarks

TypeNameUpside
StockEdgewise Therapeutics35.08%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts-216
Avg Price Target-$46.50$48.25
Last Closing Price$39.31$39.31$39.31
Upside/Downside-18.29%22.74%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Oct, 26382--13
Sep, 26382--13
Aug, 26282--12
Jul, 26272--11
Jun, 26372--12
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 21, 2026Lander EganaH.C. Wainwright$57.00$45.3225.77%45.00%
Aug 11, 2026Goldman Sachs$36.00$44.58-19.25%-8.42%
Jul 20, 2026Cory KasimovEvercore ISI$55.00$39.4639.38%39.91%
Jul 09, 2026Oppenheimer$51.00$46.3010.15%29.74%
Jul 06, 2026Debjit ChattopadhyayGuggenheim$51.00$39.8328.04%29.74%
Jun 17, 2026RBC Capital$59.00$34.5170.96%50.09%
Jun 17, 2026Paul ChoiGoldman Sachs$32.00$33.95-5.74%-18.60%
Jun 16, 2026Leerink Partners$52.00$33.2856.25%32.28%
Jun 02, 2026H.C. Wainwright$45.00$37.5719.78%14.47%
Jun 02, 2026Leonid TimashevRBC Capital$48.00$38.2725.42%22.11%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Oct 16, 2026William BlairOutperforminitialise
Oct 14, 2026H.C. WainwrightBuyBuyhold
Sep 21, 2026H.C. WainwrightBuyBuyhold
Aug 11, 2026Goldman SachsNeutralNeutralhold
Jul 20, 2026Evercore ISIOutperformOutperformhold
Jul 09, 2026OppenheimerOutperforminitialise
Jul 06, 2026GuggenheimBuyBuyhold
Jun 17, 2026Goldman SachsNeutralNeutralhold
Jun 02, 2026H.C. WainwrightBuyBuyhold
Jun 02, 2026RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.57$-1.45$-1.63---
Avg Forecast$-1.54$-1.49$-1.87$-2.23$-2.38$-1.24
High Forecast$-1.49$-1.43$-1.52$-2.00$-2.08$-1.24
Low Forecast$-1.59$-1.61$-2.25$-2.56$-2.61$-1.24
Surprise %1.95%-2.68%-12.83%---

Revenue Forecast

$0 $60M $120M $180M $240M $300M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported------
Avg Forecast---$11.40M$78.47M$263.54M
High Forecast---$11.40M$78.47M$263.54M
Low Forecast---$11.40M$78.47M$263.54M
Surprise %------

Net Income Forecast

$-170M $-151M $-132M $-113M $-94M $-75M Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-100.16M$-133.81M$-167.79M---
Avg Forecast$-100.16M$-96.86M$-120.08M$-145.07M$-149.67M$-78.89M
High Forecast$-95.09M$-90.97M$-96.96M$-127.29M$-132.84M$-78.89M
Low Forecast$-101.43M$-102.75M$-143.20M$-162.85M$-166.49M$-78.89M
Surprise %-38.15%39.74%---

EWTX Forecast FAQ

Is Edgewise Therapeutics stock a buy?

Edgewise Therapeutics stock has a consensus rating of Buy, based on 11 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 9 Buy, 2 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Edgewise Therapeutics is a favorable investment for most analysts.

What is Edgewise Therapeutics's price target?

Edgewise Therapeutics's price target, set by 11 Wall Street analysts, averages $53.1 over the next 12 months. The price target range spans from $36 at the low end to $66 at the high end, suggesting a potential 35.08% change from the previous closing price of $39.31.

How does Edgewise Therapeutics stock forecast compare to its benchmarks?

Edgewise Therapeutics's stock forecast shows a 35.08% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Edgewise Therapeutics over the past three months?

  • October 2026: 23.08% Strong Buy, 61.54% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • September 2026: 23.08% Strong Buy, 61.54% Buy, 15.38% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 16.67% Strong Buy, 66.67% Buy, 16.67% Hold, 0% Sell, 0% Strong Sell.

What is Edgewise Therapeutics’s EPS forecast?

Edgewise Therapeutics's average annual EPS forecast for its fiscal year ending in December 2026 is $-2.23, marking a 36.81% increase from the reported $-1.63 in 2025. Estimates for the following years are $-2.38 in 2027, and $-1.24 in 2028.

What is Edgewise Therapeutics’s revenue forecast?

Edgewise Therapeutics's average annual revenue forecast for its fiscal year ending in December 2026 is $11.4M, reflecting a 0% decrease from the reported $0 in 2025. The forecast for 2027 is $78.47M, and $263.54M for 2028.

What is Edgewise Therapeutics’s net income forecast?

Edgewise Therapeutics's net income forecast for the fiscal year ending in December 2026 stands at $-145M, representing a -13.54% decrease from the reported $-168M in 2025. Projections indicate $-150M in 2027, and $-78.89M in 2028.